Craft

Astria Therapeutics

Stock Price

$11.5

2024-09-05

Market Capitalization

$648.3 M

2024-09-05

Astria Therapeutics Summary

Company Summary

Overview
Astria Therapeutics (formerly known as Catabasis Pharmaceuticals) is a biopharmaceutical company focused on the discovery and development of innovative drugs to treat inflammatory conditions. There platform technology enables the discovery and development of small molecules that simultaneously and specifically target pathways in the inflammatory response. The Catabasis platform will lead to the development of novel mechanism of action therapies to safely and effectively treat inflammatory diseases.
Type
Public
Status
Active
Founded
2008
HQ
Boston, MA, US | view all locations
Website
https://astriatx.com/
Cybersecurity rating
Sectors

Key People

  • Jill C. Milne

    Jill C. Milne, Co-Founder, Chief Executive Officer

  • Kenneth Bate, Chairman

    • Noah Clauser

      Noah Clauser, Chief Financial Officer

    LocationsView all

    1 location detected

    • Boston, MA HQ

      United States

      100 High St 28th floor

    Astria Therapeutics Financials

    Summary Financials

    Net income (Q2, 2024)
    ($24.2M)
    Cash (Q2, 2024)
    $87.2M
    EBIT (Q2, 2024)
    ($28.8M)
    Enterprise value
    $546.0M

    Footer menu